Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
about
Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementAngiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubesThe optimal use of bexarotene in cutaneous T-cell lymphomaLow dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Clinical applications of Silybum marianum in oncology.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Thyroid dysfunction from antineoplastic agents.Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanism.Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's DiseaseCutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Retinoids and rexinoids in cancer prevention: from laboratory to clinic.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Cutaneous T-cell lymphomas: a review of new discoveries and treatments.U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.The utility of bexarotene in mycosis fungoides and Sézary syndrome.RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.Preclinical PET Neuroimaging of [11C]Bexarotene.Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene.Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas.[Cutaneous malignant lymphomas. Update on diagnosis and therapy of cutaneous T-cell lymphomas].[Treatment of mycosis fungoides and Sézary syndrome].A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics
P2860
Q27024076-0FC6AD22-0EFC-4B14-BB93-11C0BFFD63D3Q27316586-248ED355-FC88-4111-B00F-ACD776E3C2F8Q28305252-68328DFB-9913-4EB9-9242-7D32CCB1A9B7Q30557555-CAA05B98-6CE8-4608-9DB9-F75368F3218AQ33385966-05636512-D6E5-4DB9-A92A-D95473AC02BCQ33408049-712B158A-533E-4123-AB11-79F85431A4D2Q34634359-1E40BD95-BFA7-48DE-9194-000984D89EDFQ35022833-DCD47B1B-D66E-4789-B7FD-B665ACC675DBQ35500038-3DD7D0E1-EFAF-4A3C-B76E-2E9402B8E0E8Q35688497-E10B9C70-3578-4068-B9FC-8506639CEB57Q35749213-C79452D3-2E15-42F0-8057-184E2B1C1556Q36470196-1DFFCB78-0A3F-4EBC-A30D-9D95CC117E07Q36680198-738349C6-95D6-4DAB-84A0-7AD123C3C9F6Q37944565-A2385AD8-4A73-4E32-8251-CB9A11A8A578Q37981969-71AC3277-CBBA-4088-9442-BCE4D671DC87Q38042090-EBC81246-BE96-4C14-BF41-FCA7A14C198BQ38120303-4D88C991-041E-47C0-BE1C-A31DB0527D52Q38354440-5A404018-711E-46D4-9066-5C3E39C2546AQ38859341-7B0A9467-8106-4D5B-BA7F-430D85B3E685Q38944684-F967F648-67A5-4033-A9A3-77ED0173405CQ39253408-86C55241-E45A-4314-A551-7B00F22900ECQ41015702-97EBABE8-B45A-457C-891A-B2FDF09A8F7EQ46200338-B8CCB259-5C3F-4988-A197-DFCEE5B47141Q46758036-F07E3D1C-D6A8-4B6F-A5FB-C9CEE3032168Q46783696-B822CECB-E4B1-42D7-A052-CE9215A625CDQ48034709-6ABDC0B9-A1A1-4915-BB39-B1ABA378AB4AQ48095126-36954753-0AF3-4B21-9E99-F34D3940B6B9Q49561302-E13B3066-18D1-47D5-9976-54A9B0E104EEQ50122599-CBB434A5-8ED9-4583-B381-34789BF965B5Q51384445-D1749094-B020-4308-AA98-95AFC84EC2B9Q52888610-EA10DF31-2BBA-453F-B065-FC3F86D1C3EDQ53128681-7F353BCD-A6D2-4D89-B9B5-1F24F140FE2FQ57179000-D2998C3D-1F1C-4784-9AF1-BE3C312A88F8
P2860
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Minimizing adverse side-effect ...... l lymphoma: an expert opinion.
@ast
Minimizing adverse side-effect ...... l lymphoma: an expert opinion.
@en
type
label
Minimizing adverse side-effect ...... l lymphoma: an expert opinion.
@ast
Minimizing adverse side-effect ...... l lymphoma: an expert opinion.
@en
prefLabel
Minimizing adverse side-effect ...... l lymphoma: an expert opinion.
@ast
Minimizing adverse side-effect ...... l lymphoma: an expert opinion.
@en
P2093
P2860
P1476
Minimizing adverse side-effect ...... l lymphoma: an expert opinion.
@en
P2093
Gniadecki R
Schwandt P
Whittaker S
P2860
P304
P356
10.1111/J.1365-2133.2006.07329.X
P407
P577
2006-08-01T00:00:00Z